Cesca Therapeutics Inc (NASDAQ:KOOL) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 208,500 shares, an increase of 14.1% from the September 30th total of 182,700 shares. Based on an average trading volume of 202,800 shares, the short-interest ratio is currently 1.0 days. Approximately 12.1% of the company’s stock are sold short.
Shares of KOOL opened at $5.14 on Wednesday. The firm has a market cap of $11.57 million, a PE ratio of -1.43 and a beta of 1.07. The company has a current ratio of 1.52, a quick ratio of 0.91 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $5.65 and a two-hundred day simple moving average of $3.24. Cesca Therapeutics has a 1-year low of $2.10 and a 1-year high of $7.00.
Cesca Therapeutics (NASDAQ:KOOL) last announced its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.13. The business had revenue of $4.31 million during the quarter, compared to analyst estimates of $3.40 million. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. As a group, research analysts forecast that Cesca Therapeutics will post -0.26 EPS for the current fiscal year.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Tuesday, August 20th. ValuEngine upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Finally, HC Wainwright restated a “buy” rating and issued a $7.50 price objective (up from $6.50) on shares of Cesca Therapeutics in a report on Thursday, October 3rd.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.